BNP Paribas Financial Markets decreased its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 32.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 39,643 shares of the company's stock after selling 18,800 shares during the quarter. BNP Paribas Financial Markets' holdings in HUTCHMED were worth $571,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. XY Capital Ltd bought a new position in shares of HUTCHMED in the fourth quarter worth $673,000. ABC Arbitrage SA bought a new position in HUTCHMED in the 4th quarter worth about $500,000. Jane Street Group LLC boosted its stake in HUTCHMED by 54.7% in the 4th quarter. Jane Street Group LLC now owns 97,470 shares of the company's stock worth $1,405,000 after purchasing an additional 34,473 shares during the period. Renaissance Technologies LLC grew its holdings in HUTCHMED by 18.4% during the 4th quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock valued at $2,717,000 after buying an additional 29,239 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of HUTCHMED during the fourth quarter valued at about $261,000. Hedge funds and other institutional investors own 8.82% of the company's stock.
HUTCHMED Stock Up 2.5%
HUTCHMED stock traded up $0.34 during midday trading on Thursday, hitting $13.57. 9,232 shares of the company's stock were exchanged, compared to its average volume of 100,241. The stock has a 50-day moving average price of $14.12 and a two-hundred day moving average price of $14.92. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $21.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
Wall Street Analyst Weigh In
A number of research firms have recently commented on HCM. Wall Street Zen lowered shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. HSBC downgraded shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.
Check Out Our Latest Research Report on HUTCHMED
About HUTCHMED
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
